Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Dec 15 2023

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has issued a press release announcing the receipt of final approval from the USFDA for Darunavir Tablets in various strengths, along with tentative approval for additional strengths. The product will be manufactured at Zydus's facility in Ahmedabad, India, and the company has a significant number of approvals and filings with the USFDA.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated December 15, 2023, titled "Zydus receives final approval from the USFDA for Darunavir Tablets 600 mg and 800 mg, and tentative approval for 75 mg and 150 mg tablets".

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases